Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc., a leading biopharmaceutical company headquartered in the United States, focuses on developing innovative therapies for liver and metabolic diseases. Founded in 2011, the company has made significant strides in the industry, particularly with its flagship product, resmetirom, which targets non-alcoholic steatohepatitis (NASH) and other liver conditions.
Madrigal's commitment to advancing treatment options has positioned it as a key player in the biopharmaceutical sector, with a strong emphasis on research and development. The company’s unique approach to drug development, combined with its robust pipeline, has garnered attention and recognition within the industry. With a focus on improving patient outcomes, Madrigal Pharmaceuticals continues to pave the way for breakthroughs in metabolic health.
-20 vs industry average
Madrigal Pharmaceuticals’s score of 18 is lower than 33% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Madrigal Pharmaceuticals?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has reduced its overall emissions by 19% since 0
Reported emissions
No reported emissions data is available for Madrigal Pharmaceuticals yet.
Madrigal Pharmaceuticals's reported carbon emissions
Madrigal Pharmaceuticals, headquartered in the US, currently does not report any specific carbon emissions data, as there are no available figures for emissions in kg CO2e. Additionally, the company has not established any documented reduction targets or climate pledges.
As a result, there is no information on their Scope 1, 2, or 3 emissions, nor any significant achievements in emissions reduction. Without specific data or commitments, it is unclear how Madrigal Pharmaceuticals is addressing climate change or contributing to sustainability efforts within the pharmaceutical industry.
The absence of emissions data and reduction initiatives highlights a potential area for improvement in transparency and accountability regarding their environmental impact.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Madrigal Pharmaceuticals’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Madrigal Pharmaceuticals yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Emissions comparison with industry peers
View similar organisations
Madrigal Pharmaceuticals
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project